Antibody-drug conjugates (ADC) are an emerging drug class that utilizes antibodies to improve cytotoxic drug targeting for cancer treatment. ADC in current clinical trials achieve a compromise between potency and physicochemical/pharmacokinetic properties by conjugating potent cytotoxins directly to an antibody at a 4:1 or less stoichiometric ratio. Herein we report a novel, polyacetal polymer-based platform for creating ADC that use poly-1-hydroxymethylethylene hydroxymethyl-formal (PHF), also known as Fleximer®.
Introduction
0.660 g, 5.40 mmol) were dissolved in DCM (15 mL) at 0°C. The reagent solutions were combined and stirred at 0°C for 1 hour, brought to room temperature and stirred for an additional 2 hours. The resulting solution was diluted with DCM (50 mL), washed with water, and extracted (2x) with aqueous citric acid (1% w/v). The combined citric acid washes were treated with solid sodium bicarbonate, extracted with DCM, dried over sodium sulfate, and vacuum-concentrated. Crude HPV-Boc-alanine (1.4 g) was dissolved in DCM (55 mL) and treated with trifluoroacetic acid (TFA; 5.5 mL) at 0°C for 1 hour.
Following solvent evaporation, the crude product was dissolved in dimethylsulfoxide (DMSO) and purified by preparative reversed-phase HPLC. Lyophilization of productcontaining fractions yielded HPV-Ala-NH 2 trifluoroacetate salt as an off-white amorphous solid (59% yield; HPLC purity 96%; MS (ESI+) m/z: 883.4 (M+1)). 
Poly-1-hydroxymethylethylene hydroxymethyl-formal (PHF, III)
The Fleximer ® polymer backbone, PHF, was prepared as previously described (14, 17, 18 ). structural unit) in dimethylacetamide (DMA; 300 mL) and anhydrous pyridine (33.3 mL).
PHF-glutaric acid (PHF-
The reaction mixture was stirred at 60°C for 18 hours. Solvents were removed under reduced pressure and the resulting thick oil was dissolved in water (100 mL). The pH was adjusted to 6.0-6.5 with 5N NaOH. The resulting clear solution was diluted to 200 mL with water, filtered through a 0.2-micron filter, and purified by diafiltration using a membrane filter (3 kDa MWCO). Water was removed by lyophilization yielding PHF-GA as a white solid (1.28 g; 48% yield). 25% of total PHF monomer units were substituted with glutaric acid, as determined by 
Pyridyl disulfide (SSPy)-modified PHF-GA (PHF-GA-SSPy, V)
PHF-GA (1.63 g, 11.12 mmol) was dissolved in water (10 mL) and Nhydroxysuccinimide (NHS; 0.154 g, 1.33 mmol) was added. The mixture was cooled to 0°C and an aqueous solution of 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC; 0.256 g, 1.33 mmol) was added, followed by 2-(pyridine-2-yldisulfanyl)ethaneamine hydrochloride (0.297 g, 1.33 mmol). The pH was adjusted to 5.5-6.0 and the mixture was stirred at room temperature for 18 hours. PHF-GA-SSPy was purified by diafiltration and lyophilized to a white solid (1.66 g; 86% yield). The SSPy group content was 3% mol relative to PHF monomer units, as determined by spectrophotometry. methylene and methyne protons, PHF); 3.3-2.8 ppm (m, 4H, methylene protons, cysteamine linker); 2.5 ppm (bt, 2H, α-methylene protons, GA); 2.3 ppm (bt, 2H, γ-methylene, GA); 2.0-1.9 ppm (bt, 2H, β-methylene protons, GA).
PHF-GA-(SH)-(Ala-HPV) (PHF-vinca, VI)
PHF-GA-SSPy (289.0 mg, 0.023 mmol) was dissolved in water (8 mL) and acetonitrile (4 mL) and cooled to 0°C. NHS (26.4 mg, 0.230 mmol) was added, followed by an aqueous solution of EDC (44.0 mg, 0.230 mmol) and HPV-Ala-NH 2 (131.45 mg, 0.138 mmol). The pH of the resulting mixture was adjusted to 6.0, and the solution was stirred at room temperature overnight. The pH was adjusted to 7.5 with 1M sodium bicarbonate, and dithiothreitol (DTT; 37.8 mg, 0.245 mmol) was added. The reaction mixture was stirred for 30 minutes, diluted to 15 mL with water, and PHF-vinca (Fleximer vinca conjugate) was purified by diafiltration (57% yield, HPV-based). The HPV content was 7.3% wt, as determined by spectrophotometry. 
Trastuzumab-MCC (VII)
Trastuzumab (10 mg) was diluted in PBS pH 7.0 (1 mL), and then a solution of succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) in DMSO (5 µL, 30 mg/mL) was added. The resulting solution was stirred at room temperature for 2 hours. Trastuzumab-MCC was purified by gel filtration on a Sephadex 
Rituximab-MCC
Rituximab-MCC was prepared in a manner analogous to that described for trastuzumab-MCC.
PHF-GA-(Ala-HPV) trastuzumab (trastuzumab-PHF-vinca, VIII)
PHF-GA-(SH)-(Ala-HPV) (11.2 mg) in water (0.5 mL) was added to trastuzumab-MCC (20 mg) in PBS pH 7.0 (2 mL). The solution was stirred at room temperature for 4 hours.
The resulting trastuzumab-PHF-vinca conjugate was purified by gel filtration on a 
PHF-GA-(Ala-HPV) rituximab (rituximab-PHF-vinca)
Rituximab-PHF-vinca was prepared using rituximab-MCC in a manner analogous to that described for trastuzumab-PHF-vinca. 
In vivo xenograft models
In vivo studies using female 9 to 10-week-old CB.17 SCID mice were conducted at 
Statistical analysis
For in vivo xenograft experiments, statistical analysis was performed by the logrank and Mann-Whitney tests using Prism v3.03 (GraphPad Software).
Plasma pharmacokinetics
NCI-N87 tumor-bearing SCID mice were used for plasma pharmacokinetic studies. Mice were hydrolyzed under basic conditions (pH > 10) and the released HPV was extracted.
The lower limit of quantification for the HPV assay was 20 ng/g.
Results

Antigen binding
To ascertain whether the conjugation of PHF-vinca to random lysine residues of the antibody had any impact on antigen affinity, the binding affinity of trastuzumab-PHFvinca was compared with that of trastuzumab alone( Table 1) 
Cytotoxic activity of trastuzumab-PHF-vinca
The in vitro cytotoxicity of trastuzumab-PHF-vinca was assessed in Her2 positive and Her2 negative cell lines. Unconjugated PHF-vinca and the small molecule vinca release product HPV were examined in parallel as controls ( Table 2 
The antitumor activity of trastuzumab-PHF-vinca was further evaluated in the Her2 (3+) BT-474 human breast cancer xenograft model. Treatment with 7.5 mg/kg antibody equivalents of trastuzumab-PHF-vinca resulted in the maximum possible TGD with 100% tumor-free survivors on day 60 and day 14 TGI of 100% (Fig. 3) . A single dose (20 mg/kg antibody equivalents) of this Fleximer ADC also produced the maximum TGD and 100% tumor-free survivors on day 60. In contrast, the non-binding control treatment, rituximab-PHF-vinca, produced only modest TGI with no partial or complete regressions.
Trastuzumab alone was inactive, and trastuzumab in combination with unconjugated PHF-vinca resulted in very modest activity. All treatments were acceptably tolerated.
To assess the effect of tumor burden in this model as well as the efficacy of lower doses, a subsequent study was performed (Fig. 4) 
Pharmacokinetics and tumor accumulation of Fleximer ADCs
The pharmacokinetic properties of trastuzumab-PHF-vinca were evaluated in SCID mice bearing NCI-N87 xenograft tumors after a single injection of 15 mg/kg antibody equivalents of trastuzumab-PHF-vinca (Fig. 5A) . The plasma concentration of total trastuzumab was monitored by ELISA. Conjugated HPV and free HPV plasma concentrations were monitored by LC/MS/MS. The plasma concentrations of total trastuzumab and conjugated HPV showed a biphasic decline after the first 5-minute sampling time point with terminal elimination half-lives of approximately 9 and 3.5 days, respectively. Plasma exposure AUC 0-inf to trastuzumab-PHF-vinca ADCs and conjugated HPV was 332 μg*day/mL and 26 μg*day/mL, respectively. The concentration of free HPV in plasma at all time points was lower than the detection limit of the assay (10 ng/mL), indicating that the plasma HPV concentration was at least 1000-fold lower than that of conjugated HPV. PHF-vinca displayed rapid plasma elimination and was not detectable beyond the 24-hour time point. With the polymer approach to ADCs described herein, we demonstrate that significantly higher DARs can be achieved while maintaining excellent drug-like qualities of the resultant ADC. Furthermore, we demonstrate that a highly potent and efficacious ADC can be constructed using a moderately potent vinca derivative as the payload drug (low nanomolar potency compared to the sub-nanomolar potency of maytansines and auristatins).
For an ADC to selectively deliver drug to a tumor it must bind to its intended target, and it was unclear a priori whether the conjugation of PHF polymers to the antibody would negatively affect this essential property. As evidenced by antigen affinity measurements, trastuzumab-PHF-vinca ADCs with a DAR of 20 maintain excellent affinity for the Her2 antigen (Table 1) . Furthermore, target-dependent cytotoxicity, a key (Table 2) .
In contrast to potency in vitro, the efficacy of an ADC in vivo may also be influenced by a number of properties, including pharmacokinetics, tumor penetration, tumor accumulation, and duration of exposure. To this end, we characterized the properties of the trastuzumab-PHF-vinca ADC in two distinct Her2 (3+) xenograft models. In the NCI-N87 gastric tumor xenograft (Fig. 2) , the trastuzumab-PHF-vinca ADC exhibits dose-dependent efficacy, with a 100% regression response rate (8 partial It has been previously demonstrated that direct drug-antibody conjugation approaches yield an exposure in vivo (AUC) that is inversely proportional to drug loading (9). Our polymer-based approach takes advantage of the highly hydrophilic nature of the polymer, which can help to compensate for the increased hydrophobicity associated with higher DARs, thereby potentially improving the physicochemical and pharmacokinetic properties of the ADC. Indeed, the plasma pharmacokinetics of trastuzumab-PHF-vinca after a single administration to NCI-N87 tumor-bearing mice supports this hypothesis. As shown in Fig. 5A , trastuzumab-PHF-vinca exhibits a favorable plasma PK profile, with 
terminal elimination half-lives of approximately 9 and 3.5 days for total trastuzumab and conjugated HPV, respectively. Furthermore, free HPV, which could potentially contribute to systemic toxicity, was undetectable. As anticipated, administration of PHFvinca without the benefit of antibody conjugation results in a rapid clearance, presumably via renal filtration of this relatively small, highly hydrophilic molecule.
Trastuzumab-PHF-vinca also exhibited robust, dose-dependent efficacy in the BT-474 breast cancer xenograft model, where dosing regimens of either 20 mg/kg qd x 1 or 7.5 mg/kg qwk x 3 resulted in the maximum possible TGD and 100% tumor-free survivors at day 60 (Fig. 3) . In this experiment, treatment with trastuzumab alone was inactive, and not surprisingly, when trastuzumab was co-administered with PHF-vinca, the combination of these two agents without the benefit of covalent conjugation resulted in only very modest activity. To further support that the efficacy of trastuzumab-PHFvinca is due to antigen-dependent tumor accumulation, the non-binding ADC rituximab-PHF-vinca was also evaluated and resulted in a modest TGI, with no partial or complete regressions.
In a second BT-474 xenograft study, the activity of trastuzumab-PHF-vinca was confirmed at even lower doses; dosing regimens of 3.5 mg/kg qwk x 3 or 10 mg/kg qd x 1 resulted in 10/10 tumor-free survivors on the final day of the study (day 87) (Fig. 4) . To assess the effect of tumor burden, treatment in one group of animals was delayed until average tumor volumes reached 344 mm The time-course study comparing total HPV drug accumulation in tumors after administration of either the antigen-binding ADC trastuzumab-PHF-vinca or the nonbinding ADC rituximab-PHF-vinca further substantiates the benefit of antigen-dependent tumor targeting (Fig. 5B) . Consistent with Her2 antigen targeting, trastuzumab-PHFvinca yielded a 4-fold greater C max and 9-fold greater AUC 0-t for total HPV in tumors relative to the non-binding ADC.
In summary, our polymer-based approach to ADCs offers a highly differentiated alternative to the conjugation platforms utilized in the ADCs that are currently in clinical development. The ability to achieve higher DARs without compromising drug-like properties and thereby produce highly efficacious ADCs utilizing moderately potent drug payloads provides a potential opportunity to expand the scope and utility of ADCs for the treatment of cancer. 
